论文部分内容阅读
目的观察奥扎格雷钠联合依达拉奉治疗脑梗死的疗效及对患者血清同型半胱氨酸(Hcy)、C反应蛋白(CRP)水平的影响。方法将204例脑梗死患者随机分为试验组和对照组各102例。2组患者均给予常规支持治疗和密切护理,试验组给予奥扎格雷钠联合依达拉奉治疗,而对照组仅给予奥扎格雷钠治疗,比较2组临床疗效及患者治疗前后血清Hcy和CRP水平变化。结果试验组患者治疗总有效率高于对照组,差异有统计学意义(P<0.05);治疗前2组患者血清Hcy与CRP水平相近,差异无统计学意义(P>0.05)。治疗后试验组降低幅度大于对照组,差异均有统计学意义(P<0.05)。结论奥扎格雷钠联合依达拉奉治疗脑梗死可有效降低患者血清Hcy和CRP水平,提高治疗效果。
Objective To observe the curative effect of ozagrel combined with edaravone on cerebral infarction and its effect on serum homocysteine (Hcy) and C-reactive protein (CRP) levels. Methods Totally 204 patients with cerebral infarction were randomly divided into experimental group and control group of 102 cases. The patients in both groups were treated with ozagrel and edaravone, while those in control group were treated with ozagrel sodium only. The clinical efficacy and serum Hcy and CRP levels were compared between the two groups before and after treatment Horizontal changes. Results The total effective rate of treatment group was significantly higher than that of control group (P <0.05). There was no significant difference between the two groups before treatment (P> 0.05). After treatment, the test group decreased more than the control group, the difference was statistically significant (P <0.05). Conclusion Ozagrel combined with edaravone can effectively reduce the level of Hcy and CRP in patients with cerebral infarction and improve the therapeutic effect.